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A b s t r a c t
Background: The issue of predicting coronary artery restenosis, especially silent, in patients following primary percutaneous
coronary intervention (PCI) has been extensively studied, however, risk factors have not been fully defined.
Aim: To asses the frequency of silent restenosis and its predictors in patients with anterior ST elevation myocardial infarction
(STEMI) treated with primary PCI and implantation of bare metal stents (BMS).
Methods: We recruited a cohort of 114 patients with first anterior STEMI treated with primary PCI within 12 hours of the
onset of symptoms, and with the left anterior descending coronary artery occlusion (TIMI 0) and successful flow restoration
(TIMI 3). A 12-lead ECG was performed before and 60 minutes after PCI. Troponin I and CK-MB were measured on admis-
sion and after six, 12 and 24 hours. Transthoracic echocardiography (TTE) was performed at discharge. Resting TTE and
coronary angiography were performed after a six month follow-up in asymptomatic patients.
Results: The frequency of silent restenosis in our study group was 23.9%. The best multivariate models in logistic regression
of restenosis prediction were: lower end-systolic volume of the left ventricle assessed two days after infarction longer lesion
and smaller reference diameter of the stented vessel.
Conclusions: Silent restenosis in patients with first anterior STEMI treated by primary PCI with the use of BMS is still frequent. The
best ways to identify patients with silent restenosis at six month follow-up, apart from the lower end systolic volume in the echocar-
diographic study, are longer narrowing in the infarct-related artery and lower reference diameter of the treated vessel.
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INTRODUCTION
Primary percutaneous coronary intervention (PCI) is, accor-
ding to the European and American guidelines, an optimal
therapy for patients with acute coronary syndrome (ACS) [1, 2].
There has been increased interest that there are more and
more patients who, despite adequate pharmacotherapy, expe-
rience restenosis at the site of intervention [3, 4–6].
Restenosis is a complex, and as yet not fully understood,
process. It is believed that restenosis is long-lasting, with va-
riable rates of progression in different individuals, and it usu-
ally takes place three to six months after successful PCI.
Animal models have shown a clear correlation between
the level of injury to the artery during PCI, and the frequency
of restenosis [7]. The use of bare metal stents (BMS) signifi-
988
www.kardiologiapolska.pl
Krystian Wita et al.
cantly slows the development of unfavourable processes, re-
ducing the risk of such mechanisms of restenosis as elastic re-
narrowing, dissection or negative remodelling. The introduc-
tion of stents has decreased the number of restenoses mainly
because the technique increases the diameter of the artery.
Even in cases of relatively large lumen loss, the remaining ca-
liber is adequate to relieve symptoms.
Restenosis may be symptomatic with the recurrence or
exacerbation of symptoms. Often, however, it is clinically si-
lent, making it more difficult to diagnose, and so delaying
therapy. This is why in our study we aimed to determine the
frequency of silent restenosis in patients with first anterior
myocardial infarction with ST elevation (STEMI) treated suc-
cessfully with PCI and implantation of BMS. We attempted
to identify the predictors of asymptomatic restenosis in the
infarct-related artery (IRA) at six month follow-up.
METHODS
Inclusion criteria
Initially, we included in our study all patients hospitalised in
our Medical Centre with first anterior STEMI treated with pri-
mary PCI within 12 hours of the onset of symptoms, and with
the amputation of left anterior descending (TIMI 0) and suc-
cessful restoration of flow (TIMI 3) followed by stent implan-
tation. Anterior STEMI was defined as chest pain lasting more
than 20 minutes and elevation of ST segment ≥ 2 mm in
precordial V1–V3 leads, elevation ≥ 1 mm in other precor-
dial leads, and I, aVL leads, or new left bundle branch block.
Finally, we included patients who presented no symptoms
over a six-month observation and who agreed to control co-
ronary angiography.
Exclusion criteria
The exclusion criteria were: previous MI, hypertrophic car-
diomyopathy, implanted pacemaker or implantable car-
dioverter-defibrillator, significant valvular diseases, women
of child-bearing potential, unsatisfactory angiographic ef-
fect of PCI, with residual value of more than 30%. The pre-
sence of angina at six month follow-up was another exclu-
sion criterion.
Electrocardiography
12-lead electrocardiography (ECG) was performed directly
before, and 60 minutes after, the PCI procedure. In the first
ECG, the following parameters were analysed: maximum ST
elevation in single lead (maximum ST elevation), sum of ST
segment elevations in the precordial I, and aVL leads (SST)
measured 60 ms after QRS complex ending. On the basis of
a second ECG, patients were qualified to the group with or
without normalisation of ST segment, following the criteria
from the TIMI 14 study: reduction of sum of elevations of ST
segment by at least 50% (SST50%).
All patients after the intervention were monitored for
24 hours using the 12-lead ECG system (DASH 4000, GE).
The time to normalisation of ST segment, defined as the reduc-
tion of elevation at least 50% from the lead with the highest
elevation (DtST50%) was analysed. The DtST50% < 61 min
was taken from ROC curve.
Biochemical studies
The levels of myocardial necrosis enzymes — troponin I,
CK-MB — were measured on admission and six, 12 and
24 hours after admission to hospital.
Coronary angiography and primary PCI
The study was performed either by transfemoral or transra-
dial approach. The choice of technique of stent implanta-
tion, and the use of GP IIb/IIIa inhibitor was left to the opera-
tor. The flow in IRA was assessed in TIMI scale before and
after PCI. Collaterals were determined with the Rentrop sca-
le. Localisation and presence of thrombus were noted. The
QCA parameters described the longitude and diameter of le-
sion. Following the optimal PCI, myocardial tissue perfusion
was assessed using the Myocardial Blush Grade (MBG) scale.
The number of balloon pre-dilations, the used pressure and
the number of stents as well as their length and diameter,
were recorded. The GP IIb/IIIa inhibitor use was noted. All
patients received BMS.
Echocardiographic study
On the day of discharge, a transthoracic echocardiographic
(TTE) study was performed. The following parameters were
measured: wall motion score index, global function of left
ventricular end-diastolic volume (LVEDV), LV end-systolic
volume (LVESV), and LV ejection fraction, measured by Simp-
son method as arithmetic mean of values from two- and four-
-dimensional projections.
Follow-up
Six months after discharge from hospital, in the group of pa-
tients without symptoms of angina, resting TTE and coronary
angiography were performed. Restenosis was defined as the
presence of a lesion narrowing the lumen of the implanted
stent by ≥ 70% (in stent restenosis — ISR) and/or the presen-
ce of a similar narrowing 5 mm proximally or distally to the
implanted stent (segmental restenosis).
Statistical analysis
Statistica 7.1 was used for statistical analysis. Continuous
variables are presented as mean ± standard deviation (SD),
and dychotomic variables are presented as numbers and
percentages. Normal distribution of data was tested with the
Kolmogorow-Smirnow, Lillefors and Shapiro-Wilk tests. The
uniformity of variances was tested by Levene, Brown and
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Forsyth tests. The comparison of values in groups with nor-
mal distribution was done with a Student t-test. For non-
-normal distribution, non-parametric tests for two groups
were performed: Kolmogorow-Smirnow, and U-Mann Whit-
ney. The predictive value of parameters was assessed in
univariate logistic regression analysis. Following the analysis
of correlation, and after exclusion of dependent variables
with logistic function and estimation by Rosenbrock and
quasi Newton, we constructed the optimal predictive mo-
del for isolating the subpopulation of patients in whom we
may expect silent restenosis. Next, its value was assessed by
checking sensitivity, specificity, accuracy, and positive and
negative predictive values. A p value < 0.05 was significant.
RESULTS
Initially, 114 patients were enrolled to the study. During
the six month follow-up, three patients died due to MI, and
19 (17%) presented symptoms of angina.
After performing coronary angiography, three patients
were selected for urgent surgical revascularisation and the
remaining subjects were qualified for angioplasty. Thus, in
the final analysis, we included 92 symptom-free patients,
whose characteristics are shown in Table 1.
On the basis of the performed control coronary angiogra-
phy, the studied population was divided into two groups. The
first comprised patients with silent restenosis (SR) — 22 (23.9%)
subjects. The second included 70 (76.1%) patients without re-
stenosis (NR). The characteristics of patients with SR and NR
are presented in Table 2. Most patients in both groups were
male. The NR group was slightly older. The SR population more
often (though not statistically significantly) had diabetes, hy-
pertension and smoked cigarettes. We less often noted dyslipi-
daemia in subjects with SR. In the group of patients with SR,
there were lower troponin I levels and the time from the onset
of pain to PCI was significantly shorter. The ECG showed diffe-
rences between the groups in terms of ST segment elevation
reduction. Angiographic analysis revealed more frequent use
of longer and narrower stents, as well as a larger number of
stents, in the patients with SR. Direct stenting was more frequ-
ent than stenting with pre-dilatation in this group.
Results of univariate analysis are shown in Table 3. The
best multivariate model in logistic regression, predicting SR
six months after the event were: lower end-systolic volume
of LV (LLVESV) assessed two days after infarction (p < 0.04),
longer lesion (p < 0.03) and smaller reference diameter of
stented vessel (p < 0.01).
On the basis of multivariate analysis, we managed to
construct an equation which may help to select patients with
the highest probability of developing SR. This is: Logit (P) =
= 5.34 – 0.03*LLVESV + 0.076*longitude of lesion – 2.01*re-
ference diameter of vessel. The constructed multivariate mo-
del is characterised by high sensitivity, specificity, positive
and negative predictive values and accuracy: 78%, 86%,
59%, 94% and 84%, respectively.
DISCUSSION
The results of many published trials over the last 20 years
have indicated that the importance of stress tests in diag-
nosing SR is low following successful PCI [8]. In our group of
92 patients with anterior STEMI, we showed that the best
predictors of SR, besides typical angiographic factors, is
LLVESV on the second day of infarction. We believe this sim-
ple echocardiographic indicator is clinically important, and
Table 1. Population characteristics
Population (n) 92
Men [%] 77.2
Age [years] 56.1 ± 9.3




Angina before infarction [%] 48.9
Time from first pain [min] 240 ± 188
Troponin I maximum [ng/mL] 31.3 ± 19.2
CK-MB maximum [U/L] 261.3 ± 224.8
Creatinine [mg/dL] 1.1 ± 0.3
LVESV [mm3] 62.7 ± 22.7
LVEDV [mm3] 104.1 ± 31.8
LVEF [%] 40.6 ± 7.1
WMSI 1.40 ± 0.20
Max. elevation ST in 1 lead [mm] 5.5 ± 2.6
SST elevations [mm] 17.3 ± 8.4
SST50% [%] YES 55.4
DtST50% [%] YES 435 ± 562
Lesion in proximal LAD [%] YES 65.9
Multivessel disease [%] 76.1
Myocardial Blush Grade scale (1–4) 1.76 ± 1.01
Collateral circulation (3–4) [%] YES 6.6
Direct stenting [%] 48.4
Longitude of stented lesion [mm] 19.5 ± 7.44
Number of stents 1.04 ± 0.20
Diameter of stented vessel [mm] 3.20±0.37
Stent diameter [mm] 3.35 ± 0.40
Stent longitude [mm] 22.1 ± 7.69
Beta-blocker [%] 99.4
Statin [%] 98.9
ACE inhibitor [%] 96.7
Acetylsalicylic acid [%] 100
Clopidogrel or ticlopidin [%] 96.7
Abciximab [%] 65.2
CK-MB — creatine kinase MB isoenzyme; LVESV — left ventricular
end-systolic volume; LVEDV — left ventricular end-diastolic volume;
LVEF — left ventricular ejection fraction; WMSI — wall motion score index;
LAD — left anterior descending; ACE — angiotensin converting enzyme
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macotherapy, as well as indications for implantation, and may
indirectly affect the technique of the procedure.
At six month follow-up, the frequency of symptomatic
restenosis was 17%. A similar rate was reported in publica-
tions concerning stable angina [9–12]. These relatively good
results in our study population are probably associated with
low frequency of diabetes mellitus and hypertension, as well
as young age. A much higher frequency (25–35%) of resteno-
sis was described in the non-STEMI population [9, 13, 14].
may help to identify patients who are at risk although they
present no symptoms.
The pathogenesis of restenosis at the site of previous an-
gioplasty has been studied for more than 20 years. It is belie-
ved that the percentage of restenosis in the site of angioplasty
with the use of BMS remains high (between 10% and 40%),
even with intensive pharmacological treatment. The know-
ledge of potential factors predisposing to restenosis after im-
plantation of a stent may influence the optimisation of phar-
Table 2. Characteristics of patients without restenosis (NR) and with silent restenosis (SR)
Parameter NR SR P
Population (n) 70 22
Men [%] 77.1 68.2 NS
Age [years] 57.9 ± 10.6 54.6 ± 8.4 NS
Diabetes mellitus [%] 8.6 18.2 NS
Hypertension [%] 35.7 45.5 NS
Dyslipidaemia [%] 55.7 40.9 NS
Smoking [%] 50.0 59.1 NS
Angina before infarction [%] 48.6 50.0 NS
Time from first pain [min] 264 ± 197 162 ± 138 < 0.03
Troponin I maximum [ng/mL] 34.7 ± 17.9 21.6 ± 19.4 < 0.05
CK-MB maximum [U/L] 281.1 ± 201.8 237.5 ± 354.1 NS
Creatinine [mg/dL] 1.04 ± 0.28 0.97 ± 0.19 NS
LVESV [mm3] 65.6 ± 24.1 53.5 ± 13.9 < 0.01
LVEDV [mm3] 107.7 ± 33.1 92.6 ± 24.4 NS
LVEF [%] 39.9 ± 7.2 41.4 ± 4.8 NS
WMSI 1.43 ± 0.21 1.31 ± 0.16 < 0.02
Max. elevation ST in 1 lead [mm] 5.6 ± 2.4 5.1 ± 3.4 NS
SST elevations [mm] 18.4 ± 9.7 14.9 ± 7.6 NS
SST50% [%] YES 55.7 54.5 NS
DtST50% [%] YES 47.1 72.7 < 0.03
Lesion in proximal LAD [%] YES 68.1 59.1 NS
Multivessel disease [%] 77.1 72.7 NS
Myocardial Blush Grade scale (1–4) 1.66 ± 1.04 1.96 ± 0.95 NS
Collateral circulation (3–4) [%] YES 2.90 18.2 < 0.03
Direct stenting [%] 28.6 51.4 < 0.03
Longitude of stented lesion [mm] 18.5 ± 5.9 22.7 ± 10.6 < 0.02
Number of stents 1.0 ± 0.1 1.1 ± 0.4 < 0.02
Diameter of stented vessel [mm] 3.3 ± 0.4 3.0 ± 0.3 < 0.02
Stent diameter [mm] 3.4 ± 0.4 3.2 ± 1.1 < 0.02
Stent longitude [mm] 21.1 ± 6.17 25.3 ± 10.9 < 0.02
Beta-blocker [%] 100 98.6 NS
Statin [%] 100 95.5 NS
ACE inhibitor [%] 95.7 100 NS
Acetylsalicylic acid [%] 100 100 NS
Clopidogrel or ticlopidin [%] 98.57 100 NS
Abciximab [%] 64.3 68.2 NS
Abbreviations as in Table 1
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The results of clinical research in which control angio-
graphy was performed six months after PCI have shown that
angiographic restenosis is more frequent than symptomatic
restenosis [15, 16]. Analysis of the results of these studies has
revealed that more than 50% of patients with restenosis have
no angina symptoms six months after PCI. We believe this
group should be carefully supervised, especially in the light of
the SWISSI II trial. The study concluded that prognosis in pa-
tients with asymptomatic restenosis after infarction is much
better in the group treated interventionally than in the group
treated conservatively [17].
The meta-analysis of studies by Ruygrok et al. [18] which
included ten trials of patients after acute MI, showed the oc-
currence of SR only in 12% of patients at six month angiogra-
phy, less often than in our population. On the other hand,
the SOPHOS study included patients with ACS but with only
one critical lesion [15].
In our trial, many predictors of SR in univariate analysis
are the same as predictors of symptomatic restenosis already
reported in literature. Angiographic indicators, such as longer
narrowing of the IRA vessel, smaller diameter of the stent or
reference vessel, or higher numbers of implanted stents are
known indicators of symptomatic restenosis [10, 19, 20]. Sur-
prisingly, the results of our trial did not confirm that diabetes
or hypertension play a role. In our population, diabetes and
hypertension were less frequent compared to other trials in
literature, which was probably due to the selected popula-
tion I (first STEMI, relatively young).
We also did not confirm the role of renal insufficiency,
another widely known indicator of restenosis [21]. Renal insuf-
ficiency was not an exclusion criterion, but creatinine levels in
both groups were within reference values, also probably as the
result of young age and few cases of diabetes mellitus.
An interesting new observation is that well functioning
collateral circulation, classified according to the Rentrop sca-
le, may predict SR. We believe that this represents typical
restenosis, and lack of stenocardia is due to well developed
collaterals.
The best multivariate model for predicting SR consisted
of longer amputated vessel, smaller diameter of reference ves-
sel, and  LLVESV [17, 18]. Lower values of troponin mean
less damage to the myocardium, and potentially better sup-
ply of blood to the coronary vessel — media and intima —
via the vasa vasorum [22–24]. This may result in less damage
to the wall of the vessel and to local rennin–angiotensin–al-
dosteron complexes, and increased proliferation of smooth
muscle cells. Paradoxically, this means pathologic healing and
restenosis. The role of the vasa vasorum in the pathological
process of atherothrombosis is not yet fully understood. Tho-
se vessels originate in response to a reactive stimulus. This
process is thought to be the source of disease by influencing
the function of the endothelium and opening the ‘gate’ for
the migration of monocytes. This leads to an inflammatory
reaction, and as a consequence to the development of reste-
nosis [24].
To the best of our knowledge, no study has indicated
such a relationship in symptomatic restenosis. That is why
the role of LLVESV in the acute phase of STEMI should un-
dergo further investigation.
Limitations of the study
The limitation of the study is the use of BMS only. Nowadays,
widely used drug-coated stents, also in ACS, mainly non-STEMI,
seem to show a lower rate of restenosis.
The results of recent trials showed a significant reduction
in repeat coronary intervention if a drug-eluting stent is used
Table 3. Predictors of silent restenosis at six month follow-up — univariate analysis
Parameter Unit odds ratio –95% confidence +95% confidence P
interval interval
Time from onset of pain [continuous value] 0.996 0.992 0.999 0.036
Troponin I max [continuous value] 0.965 0.941 0.991 0.01
CK-MB max [continuous value] 0.995 0.990 0.999 0.048
DtST50% [YES] 2.99 1.03 8.65 0.04
LVESV 0 [continuous value] 0.972 0.947 0.998 0.04
Collateral circulation 3–4 [YES] 7.44 1.23 45.02 0.03
Flow on the guidewire [YES] 3.97 1.05 14.9 0.04
Direct stenting [YES] 3.0 1.1 8.15 0.02
Longitude of lesion [continuous value] 1.07 1.005 1.114 0.03
Number of stents [continuous value] 10.89 1.04 114.46 0.04
Reference value [continuous value] 0.14 0.029 0.695 0.02
Diameter of stents [continuous value] 0.17 0.04 0.71 0.02
Abbreviations as in Table 1
992
www.kardiologiapolska.pl
Krystian Wita et al.
in STEMI, although not reducing the risk of thrombosis, repe-
ated infarction or death [25, 26]. The newest ESC guidelines
for STEMI advise further trials, with long observations, con-
cerning the safety of using drug-eluting stents in STEMI [2].
Because of the uniform population of patients confined
to first STEMI of anterior wall, the studied group consisted of
young patients (mean age 56.1 ± 9.3). Few patients were
aged over 75, a group which normally has more complex
lesions in vessels as well as more significant concomitant di-
seases, something which may determine the frequency of
symptomatic and asymptomatic restenosis.
CONCLUSIONS
The frequency of silent restenosis in patients with first ante-
rior wall STEMI treated by primary PCI with the use of BMS is
still high, reaching 23.9%. The best indicators identifying pa-
tients with SR at six month follow-up after PCI, except for LLVESV
in the echocardiographic study, were longer narrowing in the
IRA and a lower reference diameter of the treated vessel. Becau-
se of the hidden process of unfavourable remodelling and the
potential danger of another ischaemic event, it is important to
identify patients predisposed to remodelling as early as possible.
The model presented in our trial may be of use.
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S t r e s z c z e n i e
Wstęp: Ze względu na fakt, że wciąż zwiększa się populacja pacjentów z nawrotem zwężenia po pierwotnej angioplastyce
wieńcowej (PCI), mimo adekwatnej farmakoterapii, problem określenia czynników ryzyka restenozy po skutecznej pierwot-
nej PCI jest w ostatnim czasie intensywnie badany. Nawrót zwężenia może powodować objawy kliniczne, jednak u wielu
pacjentów jest bezobjawowy, co znacznie utrudnia diagnostykę i opóźnia wdrożenie właściwego leczenia.
Cel: W niniejszej pracy w 6-miesięcznej obserwacji oceniano częstość i czynniki ryzyka wystąpienia bezobjawowej restenozy
u chorych z pierwszym w życiu zawałem z uniesieniem odcinka ST (STEMI) ściany przedniej, leczonych pierwotną PCI
z implantacją stentów nieuwalniających leku (BMS).
Metody: Do badania włączono 114 osób z pierwszym w życiu STEMI ściany przedniej, z zamknięciem tętnicy przedniej
zstępującej (TIMI 0), leczonych pierwotną PCI w ciągu 12 godzin od początku objawów, skutecznym udrożnieniu tętnicy
(TIMI 3) i implantacją BMS. Badanie EKG wykonywano przed i 60 minut po PCI, wartości troponiny I i CK-MB oznaczano
przy przyjęciu, a następnie po 6, 12 i 24 godzinach. Przezklatkowe badanie echokardiograficzne wykonano 2 dni po zawale
— przed wypisem ze szpitala. Po 6-miesięcznej obserwacji u pacjentów bez objawów klinicznych ponownie wykonano
spoczynkowe przezklatkowe badanie echokardiograficzne i angiografię tętnic wieńcowych.
Wyniki: Częstość występowania bezobjawowej restenozy w badanej grupie pacjentów wynosiła 23,9%. W analizie wielo-
czynnikowej metodą logistycznej regresji najlepiej przewidywały nawrót zwężenia w tętnicy dozawałowej (IRA) — niska
końcowoskurczowa objętość lewej komory oceniana 2 dni po zawale, dłuższa blaszka miażdżycowa i mniejsza średnica IRA.
Wnioski: Częstość występowania bezobjawowego nawrotu zwężenia u pacjentów po pierwszym w życiu STEMI ściany
przedniej leczonych skuteczną PCI z użyciem BMS jest wciąż wysoka. Najlepszymi czynnikami predykcyjnymi identyfikują-
cymi chorych z nawrotem zwężenia, poza niską objętością końcowoskurczową lewej komory w badaniu echokardiograficz-
nym, jest dłuższe zwężenie i mała średnica IRA.
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